Combination of Capecitabine and Oxaliplatin is an Effective Treatment Option for Advanced Neuroendocrine Tumors. - Wikidata - wikimedia - TriplyDB

Combination of Capecitabine and Oxaliplatin is an Effective Treatment Option for Advanced Neuroendocrine Tumors.

Combination of Capecitabine and Oxaliplatin is an Effective Treatment Option for Advanced Neuroendocrine Tumors.

http://www.wikidata.org/entity/Q37246135

about

Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program.Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour group Cytotoxic chemotherapy for pancreatic neuroendocrine tumors.Gemcitabine and oxaliplatin or alkylating agents for neuroendocrine tumors: Comparison of efficacy and search for predictive factors guiding treatment choice.Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer.Functional pancreatic neuroendocrine tumour causing Cushing's syndrome: the effect of chemotherapy on clinical symptoms.Treatment of High-Grade Metastatic Pancreatic Neuroendocrine Carcinoma with FOLFIRINOX.

P2860

Q26768483-9F612D0E-6FC7-48AB-80FF-21D7FAF14399 Q36184629-ED9ACDCA-419D-4843-A372-D01BE057BD34 Q37629658-15468152-5F95-422B-B7F8-BB0868A72CF1 Q38458505-13212CE5-CDA4-4107-8473-3368CC9FEA0A Q40853524-2AB60138-7C0A-41E8-825E-15021C672460 Q41683785-C4BB4596-981F-4CF2-9C1E-7110998C4583 Q47106155-AD471937-96F2-4D86-AC4E-2475B6FCD692 Q53622588-C3DC1F2A-21CE-4B6D-8123-596362DCBDCD

P2860

Combination of Capecitabine and Oxaliplatin is an Effective Treatment Option for Advanced Neuroendocrine Tumors.

http://www.wikidata.org/entity/Q37246135

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 24 September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Combination of Capecitabine an ...... dvanced Neuroendocrine Tumors.

@en

Combination of Capecitabine an ...... dvanced Neuroendocrine Tumors.

@nl

type

label

Combination of Capecitabine an ...... dvanced Neuroendocrine Tumors.

@en

Combination of Capecitabine an ...... dvanced Neuroendocrine Tumors.

@nl

prefLabel

Combination of Capecitabine an ...... dvanced Neuroendocrine Tumors.

@en

Combination of Capecitabine an ...... dvanced Neuroendocrine Tumors.

@nl

P1433

Q37246135-1E3785BA-5549-4C52-A89A-DF1C4BBFAE6B

P1476

Q37246135-E55B49C2-7560-45DF-8DDC-D310CC102299

P2093

Q37246135-0428DC84-D1F5-4341-B3E8-59BFDF69500B

Q37246135-0A8E8867-3645-454F-A785-A94C74E780C9

Q37246135-44A7AAF5-0450-4893-9239-9A1E13C6AC36

Q37246135-456744E4-D347-4704-927B-F88C82B36261

Q37246135-46C22A32-1DE8-4840-9399-8EFD0DED40F8

Q37246135-7823AFB7-EDD0-400B-9DA8-EA1A24BAA6EC

Q37246135-AF41C703-C5B2-4585-82EC-9BD8183D78E2

P2860

Q37246135-01E3D0CF-1C40-4C3A-95C1-4E453C75B3F6

Q37246135-0F2F479F-D1AE-41EF-9CCE-7DF14A26B018

Q37246135-19BE4934-C63D-41E1-A603-321A91E76485

Q37246135-2597A64A-F036-4023-AB32-80A1F155E4D6

Q37246135-364E11CF-8F5B-417B-84EE-6762BDC260C7

Q37246135-5A361F00-8EE3-4EDF-94B0-98885143A951

Q37246135-77B31A1D-5140-44A5-A567-37546C8D907A

Q37246135-7BDB1240-A8C3-440A-B73E-09D89EDE0201

Q37246135-7C2302EB-B943-457C-A2F4-ED6017CC9C69

Q37246135-7CFA571F-3695-42FA-86FB-7D78F0573023

P304

Q37246135-A057422A-C5E2-48E9-9E99-92DF37E2991D

P31

Q37246135-2BA12C62-DCB9-42EB-9B17-B07F72138EAE

P356

Q37246135-9E907516-78EC-433E-AFDF-900F248F9586

P433

Q37246135-D7446D32-5856-4ADC-A8DC-D0E56A0D36EE

P478

Q37246135-4998DED6-EEC5-4FDB-9C77-08C1B93BD782

P577

Q37246135-EEF8A1CA-AC47-4D25-BE8B-04EAE8F8852B

P5875

Q37246135-2DE7719E-DBB6-46FF-8F23-BD0B18813573

P698

Q37246135-1209F1E0-FA12-45BB-8AC3-85A915E35884

P932

Q37246135-45B0B969-58EF-4F5E-A727-372BC849F064

P356

P1433

P1476

Combination of Capecitabine an ...... dvanced Neuroendocrine Tumors.

@en

P2093

Frederico P Costa

http://www.w3.org/2001/XMLSchema#string

Laura Testa

http://www.w3.org/2001/XMLSchema#string

Luiz T Siqueira

http://www.w3.org/2001/XMLSchema#string

Marina Sahade

http://www.w3.org/2001/XMLSchema#string

Paulo M Hoff

http://www.w3.org/2001/XMLSchema#string

Rachel P Riechelmann

http://www.w3.org/2001/XMLSchema#string

Renata Ferrarotto

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Gastroenteropancreatic neuroendocrine tumours

Reporting results of cancer treatment

Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms.

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Everolimus for advanced pancreatic neuroendocrine tumors.

Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors.

First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.

Phase II study of pemetrexed in patients with advanced neuroendocrine tumors.

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

P304

e35

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4081/RT.2013.E35

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2013-09-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258216142

http://www.w3.org/2001/XMLSchema#string

P698

24179647

http://www.w3.org/2001/XMLSchema#string

P932

3804810

http://www.w3.org/2001/XMLSchema#string